Market Cap 25.88M
Revenue (ttm) 710,000.00
Net Income (ttm) -11.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,676.06%
Debt to Equity Ratio 0.00
Volume 368,200
Avg Vol 171,982
Day's Range N/A - N/A
Shares Out 24.89M
Stochastic %K 100%
Beta 0.48
Analysts Strong Sell
Price Target $4.50

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
Makingmillions192
Makingmillions192 Apr. 7 at 2:35 PM
$LEXX 100k+ block just bought 👀 Just keep churning and burning guys. Consolidation continues.
0 · Reply
EliteEngineer14
EliteEngineer14 Apr. 7 at 2:25 PM
$LEXX thanks to whoever just sold me their shares at $0.91 😂
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 1:58 PM
$LEXX Yup FUDsters are still launching attacks with tiny sells. Can’t believe they are still wasting their time and money. Desperate is an understatement. Can’t wait to see these pigs cover at 10x
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Apr. 7 at 1:49 PM
$LEXX low vol tomfoolery from mms as per usual....
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 1:42 PM
$LEXX Churn and burn boys 🚂 💨 📈 Waiting for the FUD queens to show up 😂
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 1:34 PM
$LEXX The "2026 Pipeline" is Now Public This update quietly dropped a major piece of news: Lexaria is moving beyond semaglutide and tirzepatide. They announced plans to test: • Retatrutide: Eli Lilly’s "Triple Agonist" (the "Godzilla" of weight loss drugs). • Amycretin: Novo Nordisk’s next-gen oral co-agonist. • Orforglipron: Now officially on the "potential testing" list. IMO this is strategic positioning for the April 30th deadline. The timing of this "Applause" PR—right as the stock is breaking out past the $1.00 level—is designed to remind the market (and potential M&A partners) of Lexaria's 65-patent moat. * It reinforces the idea that whoever wins the "Obesity Wars" will likely need DehydraTECH to ensure their drug is the most "tolerable" one on the market.
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 1:31 PM
$LEXX According to Eli Lilly, “The most common side effects of Foundayo™ include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo.” In various studies performed during the past ~2 years, DehydraTECH has already been evaluated orally with semaglutide, liraglutide, and tirzepatide and has successfully reduced side effects with each drug. For example, in Study GLP-1-H24-4, Lexaria reported a 47.9% reduction in the total quantity of adverse events derived from oral DehydraTECH-semaglutide vs. Rybelsus™. $LLY $PFE $NVO
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 1:28 PM
$LEXX https://www.thenewswire.com/press-releases/1LYzFO9WY-lexaria-applauds-eli-lilly-s-foundayo-tm-drug-approval.html
0 · Reply
Traveller22
Traveller22 Apr. 7 at 1:06 PM
$LEXX hopefully the animal studies get started soon as those results will dial in the next rounds of human pilot studies and eventual IP. Combined with the existing discussions from the past studies we might just have a transformational year.
0 · Reply
cashonthebarrelhead
cashonthebarrelhead Apr. 7 at 1:00 PM
$LEXX I will be taking 22-23k shares this afternoon when my money clears. The way to beat this shorts and buy the shares and squeeze the F out of theme to cover. Everyone buy as many as they can today to start their pain.
0 · Reply
Latest News on LEXX
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval

Apr 7, 2026, 9:10 AM EDT - 1 hour ago

Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval


Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval

Apr 7, 2026, 9:10 AM EDT - 1 hour ago

Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval


Lexaria to Begin New Human Clinical Study in GLP-1

Apr 1, 2026, 9:20 AM EDT - 6 days ago

Lexaria to Begin New Human Clinical Study in GLP-1


Lexaria's Robust Patent Portfolio Continues to Grow

Mar 26, 2026, 9:20 AM EDT - 12 days ago

Lexaria's Robust Patent Portfolio Continues to Grow


Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Mar 24, 2026, 9:15 AM EDT - 14 days ago

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry


Lexaria Announces New R&D Plans for 2026

Mar 4, 2026, 9:25 AM EST - 4 weeks ago

Lexaria Announces New R&D Plans for 2026


Lexaria Awarded Six Additional Patents

Jan 22, 2026, 9:20 AM EST - 2 months ago

Lexaria Awarded Six Additional Patents


Lexaria Releases Annual Letter from the CEO

Jan 12, 2026, 9:10 AM EST - 3 months ago

Lexaria Releases Annual Letter from the CEO


Lexaria Bioscience Corp. Provides Strategic Update

Oct 9, 2025, 9:20 AM EDT - 6 months ago

Lexaria Bioscience Corp. Provides Strategic Update


GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Aug 6, 2025, 9:20 AM EDT - 8 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies


Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 1 year ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4


Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Lexaria's Human GLP-1 Study #5 Begins Dosing


Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 19, 2024, 9:05 AM EST - 1 year ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing


Lexaria Forms New Scientific Advisory Board

Dec 18, 2024, 9:25 AM EST - 1 year ago

Lexaria Forms New Scientific Advisory Board


Makingmillions192
Makingmillions192 Apr. 7 at 2:35 PM
$LEXX 100k+ block just bought 👀 Just keep churning and burning guys. Consolidation continues.
0 · Reply
EliteEngineer14
EliteEngineer14 Apr. 7 at 2:25 PM
$LEXX thanks to whoever just sold me their shares at $0.91 😂
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 1:58 PM
$LEXX Yup FUDsters are still launching attacks with tiny sells. Can’t believe they are still wasting their time and money. Desperate is an understatement. Can’t wait to see these pigs cover at 10x
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Apr. 7 at 1:49 PM
$LEXX low vol tomfoolery from mms as per usual....
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 1:42 PM
$LEXX Churn and burn boys 🚂 💨 📈 Waiting for the FUD queens to show up 😂
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 1:34 PM
$LEXX The "2026 Pipeline" is Now Public This update quietly dropped a major piece of news: Lexaria is moving beyond semaglutide and tirzepatide. They announced plans to test: • Retatrutide: Eli Lilly’s "Triple Agonist" (the "Godzilla" of weight loss drugs). • Amycretin: Novo Nordisk’s next-gen oral co-agonist. • Orforglipron: Now officially on the "potential testing" list. IMO this is strategic positioning for the April 30th deadline. The timing of this "Applause" PR—right as the stock is breaking out past the $1.00 level—is designed to remind the market (and potential M&A partners) of Lexaria's 65-patent moat. * It reinforces the idea that whoever wins the "Obesity Wars" will likely need DehydraTECH to ensure their drug is the most "tolerable" one on the market.
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 1:31 PM
$LEXX According to Eli Lilly, “The most common side effects of Foundayo™ include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo.” In various studies performed during the past ~2 years, DehydraTECH has already been evaluated orally with semaglutide, liraglutide, and tirzepatide and has successfully reduced side effects with each drug. For example, in Study GLP-1-H24-4, Lexaria reported a 47.9% reduction in the total quantity of adverse events derived from oral DehydraTECH-semaglutide vs. Rybelsus™. $LLY $PFE $NVO
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 1:28 PM
$LEXX https://www.thenewswire.com/press-releases/1LYzFO9WY-lexaria-applauds-eli-lilly-s-foundayo-tm-drug-approval.html
0 · Reply
Traveller22
Traveller22 Apr. 7 at 1:06 PM
$LEXX hopefully the animal studies get started soon as those results will dial in the next rounds of human pilot studies and eventual IP. Combined with the existing discussions from the past studies we might just have a transformational year.
0 · Reply
cashonthebarrelhead
cashonthebarrelhead Apr. 7 at 1:00 PM
$LEXX I will be taking 22-23k shares this afternoon when my money clears. The way to beat this shorts and buy the shares and squeeze the F out of theme to cover. Everyone buy as many as they can today to start their pain.
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 12:33 PM
$LEXX The stock is currently locked in a high-stakes battle between a technical breakout and a desperate short attack. Technical Breakdown • Daily Chart: We’ve cleared the 100-day SMA ($0.81). And the 200-day SMA ($0.88). This level, once a ceiling, is now firm support. The MACD shows a bullish expansion, while the RSI (75-80) sits in the power zone, typical of high-momentum runs. • Weekly Chart: The long-term & V-Bottom is nearly complete. Clearing $1.10 opens a resistance void up to $1.50–$1.70. • The Squeeze: With 373k shares short and a 1.5-day cover ratio, any positive news will force a violent covering rally. Shorts are trying to break the $1.00 psychological floor, but the trend is firmly bullish. With the April 30th MTA deadline looming and the cap table leaner after the Bunka gift, the risk is heavily skewed to the upside. The tape doesn’t lie 📈 $LLY $JAZZ $TEVA
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 12:20 PM
$LEXX The more I see these shorts sweat the more I know we are about to squeeze 🥵
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 12:19 PM
$LEXX A whole generation of short bag holders that is 👋 You and Loston are going to remember this one for a long long time.
0 · Reply
Titosrbija
Titosrbija Apr. 7 at 11:58 AM
$LEXX New generation of bag holder unfolding
0 · Reply
Shubeedoo
Shubeedoo Apr. 7 at 11:53 AM
$LEXX Agree with you cash, only a short shows that hand.
0 · Reply
cashonthebarrelhead
cashonthebarrelhead Apr. 7 at 11:37 AM
$LEXX there was about 93K shares at the close left 1.02-1.06. Someone either trying manipulating the F out of this, shorting or just wants out. The thing is in basicly little volume, who would stack and block the ask like that spreading them out now, and take all the able to borrow shares. Its clear imo.
0 · Reply
Makingmillions192
Makingmillions192 Apr. 7 at 9:37 AM
$LEXX The trend is your friend 📈 🚀 It’s a great day to have a great day.
0 · Reply
jowzakiki
jowzakiki Apr. 7 at 5:15 AM
$LEXX I hope the price breaks through $1.06 today.ฃ
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Apr. 6 at 11:49 PM
$LEXX green days becoming the norm now...
0 · Reply
Makingmillions192
Makingmillions192 Apr. 6 at 10:21 PM
$LEXX Great consolidation day gents 💪 ⏰ Tick tock until 🧨 🚀
0 · Reply
Shubeedoo
Shubeedoo Apr. 6 at 8:18 PM
$LEXX Looks like the $1.06 got taken out. Should be smooth sailing tomorrow
1 · Reply
cashonthebarrelhead
cashonthebarrelhead Apr. 6 at 8:06 PM
$LEXX Well someone got a chunk at the close, I can scoop a bunch tomorrow. Later guys.
0 · Reply